Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition

Stock Track

Nov 05

Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price tumble 5.00% in pre-market trading on Wednesday, following the release of disappointing third-quarter financial results and the announcement of a significant leadership change.

The biopharmaceutical company reported a Q3 operating loss of $172.202 million, with net income falling to negative $162.253 million. More alarmingly, Recursion's Q3 operating revenue came in at just $4.983 million, significantly below the IBES estimate of $17 million. This substantial revenue miss likely contributed to investor concerns about the company's near-term financial performance.

Adding to the market's unease, Recursion announced a major leadership transition. Effective January 1, 2026, Najat Khan, Ph.D., currently serving as Chief R&D and Commercial Officer, will succeed Chris Gibson, Ph.D., as CEO and President. Gibson, the co-founder and current CEO, will transition to the role of Chairman of the Board. While leadership changes can sometimes be viewed positively, the timing alongside weak financial results may have amplified investor uncertainty about the company's future direction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1194286932"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194286932\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194286932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194286932","market":"nz","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition","media":"Stock Track","content":"<p>Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price tumble 5.00% in pre-market trading on Wednesday, following the release of disappointing third-quarter financial results and the announcement of a significant leadership change.</p>\n\n<p>The biopharmaceutical company reported a Q3 operating loss of $172.202 million, with net income falling to negative $162.253 million. More alarmingly, Recursion's Q3 operating revenue came in at just $4.983 million, significantly below the IBES estimate of $17 million. This substantial revenue miss likely contributed to investor concerns about the company's near-term financial performance.</p>\n\n<p>Adding to the market's unease, Recursion announced a major leadership transition. Effective January 1, 2026, Najat Khan, Ph.D., currently serving as Chief R&D and Commercial Officer, will succeed Chris Gibson, Ph.D., as CEO and President. Gibson, the co-founder and current CEO, will transition to the role of Chairman of the Board. While leadership changes can sometimes be viewed positively, the timing alongside weak financial results may have amplified investor uncertainty about the company's future direction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price tumble 5.00% in pre-market trading on Wednesday, following the release of disappointing third-quarter financial results and the announcement of a significant leadership change.</p>\n\n<p>The biopharmaceutical company reported a Q3 operating loss of $172.202 million, with net income falling to negative $162.253 million. More alarmingly, Recursion's Q3 operating revenue came in at just $4.983 million, significantly below the IBES estimate of $17 million. This substantial revenue miss likely contributed to investor concerns about the company's near-term financial performance.</p>\n\n<p>Adding to the market's unease, Recursion announced a major leadership transition. Effective January 1, 2026, Najat Khan, Ph.D., currently serving as Chief R&D and Commercial Officer, will succeed Chris Gibson, Ph.D., as CEO and President. Gibson, the co-founder and current CEO, will transition to the role of Chairman of the Board. While leadership changes can sometimes be viewed positively, the timing alongside weak financial results may have amplified investor uncertainty about the company's future direction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1194286932","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194286932","pubTimestamp":1762342467,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price tumble 5.00% in pre-market trading on Wednesday, following the release of disappointing third-quarter financial results and the announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"个股追踪|Recursion Pharmaceuticals盘前暴跌5%受Q3业绩疲弱及CEO换届影响","themeId":"e0b11eb1759d2fa3a59526eca8ac097c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price tumble 5.00% in pre-market trading on Wednesday, following the release of disappointing third-quarter financial results and the announcement of a significant leadership change.\nThe biopharmaceutical company reported a Q3 operating loss of $172.202 million, with net income falling to negative $162.253 million. More alarmingly, Recursion's Q3 operating revenue came in at just $4.983 million, significantly below the IBES estimate of $17 million. This substantial revenue miss likely contributed to investor concerns about the company's near-term financial performance.\nAdding to the market's unease, Recursion announced a major leadership transition. Effective January 1, 2026, Najat Khan, Ph.D., currently serving as Chief R&D and Commercial Officer, will succeed Chris Gibson, Ph.D., as CEO and President. Gibson, the co-founder and current CEO, will transition to the role of Chairman of the Board. While leadership changes can sometimes be viewed positively, the timing alongside weak financial results may have amplified investor uncertainty about the company's future direction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}